Metabolic & Cardiometabolic
statins causes cognitive impairment
In plain terms: Do statins cause cognitive impairment?
Part of: 💊 statins
The directional claim is not supported: blinded RCTs and meta-analyses are largely null/reassuring, finding no consistent adverse effect on cognition.
📅 Last reviewed: 2026-07-14 ⓘ
Evidence ladder
How far up the ladder this claim has climbed. A high consensus on a low rung means "consistent so far," not "proven in people."
Top evidence so far: All trials, pooled (Meta-analysis)
How the studies fall
What the evidence shows
The directional claim is not supported. Blinded randomised trials that measured cognition prospectively, including the Heart Protection Study and PROSPER in 5,804 older adults at vascular risk, found no difference against placebo, meta-analyses of trials find no impairment, and a 125-million-patient records analysis associates statin use with lower Alzheimer's incidence.
The evidence (11)
| Source | Grade | Stance | Quality | Finding |
|---|---|---|---|---|
| Heart Protection Study Collaborative Group 2002 · Lancet 2002 Jul 6;360(9326):7-22 | RCT | tested-null | high | HPS: prospectively assessed cognitive function and found no significant difference between simvastatin and placebo in 20,536 participants. |
| Ott BR, Daiello LA, Dahabreh IJ, Springate BA, Bixby K, Murali M, Trikalinos TA 2015 · J Gen Intern Med | meta-analysis | contradicts | high | Systematic review/meta-analysis of RCTs: statins did not impair cognition; pooled data showed no significant adverse effect on cognitive performance (directly contradicts the claim). |
| Shepherd J, Blauw GJ, Murphy MB, Bollen EL, Buckley BM, Cobbe SM, Ford I, Gaw A, Hyland M, Jukema JW, Kamper AM, Macfarlane PW, Meinders AE, Norrie J, Packard CJ, Perry IJ, Stott DJ, Sweeney BJ, Twomey C, Westendorp RG, PROSPER study group. PROspective Study of Pravastatin in the Elderly at Risk 2002 · Lancet | RCT | contradicts | high | PROSPER RCT, 5804 adults aged 70-82 at vascular risk, pravastatin 40 mg/d vs placebo, mean 3.2 y: 'Pravastatin had no significant effect on cognitive function or disability.' A randomised null on this directional claim, so contradicts (CONVENTIONS §5). Cognition was a secondary endpoint; the abstract gives no estimate or CI. |
| Novak DA, Saleem N, Gerhardt PC, Maestas D, Kejriwal N, Vaezazizi E, Murray I, Al-Khoury L 2026 · J Alzheimers Dis | observational | contradicts | moderate | Real-world EHR analysis of 125M patients links statin use to lower incident Alzheimer's risk (RR 0.69), not higher. |
| Richardson K, Schoen M, French B, Umscheid CA, Mitchell MD, Arnold SE, Heidenreich PA, Rader DJ, deGoma EM 2013 · Ann Intern Med | meta-analysis | contradicts | moderate | Systematic review: found no adverse effect of statins on cognition in good-quality data; cognitive concerns rest mainly on rare anecdotal post-marketing reports. |
| Ying H, Wang J, Shen Z, Wang M, Zhou B 2021 · Cardiovasc Drugs Ther | meta-analysis | contradicts | moderate | Meta-analysis of contemporary lipid-lowering agents shows LDL-C lowering does not impair cognitive function. |
| De Giorgi R, Waters S, Gillespie AL, Quinton AMG, Colwell MJ, Murphy SE, Cowen PJ, Harmer CJ 2025 · Psychol Med | RCT | tested-null | moderate | 28-day randomized simvastatin trial in healthy at-risk adults found no impairment of working memory or reward learning versus placebo. |
| Adhikari A, Tripathy S, Chuzi S, Peterson J, Stone NJ 2021 · J Clin Lipidol | observational | contradicts | moderate | Systematic review of RCTs and cohorts (1.4M participants) finds no adverse cognitive effects or excess dementia with statins in adults >=60. |
| Liu Y, Kunutsor SK 2026 · Geroscience | meta-analysis | contradicts | high | Narrative review: 'This narrative review critically appraises current evidence on the relationship between statin use and cognitive outcomes in older adults'. Summarises that 'Most RCTs have not demonstrated a harmful effect of statins on cognition'. No pooling. Review — zero weight. |
| Sternberg Z, Podolsky RE, Yu J, Hua S, Halvorsen S, Schaller BJ 2026 · J Prev Alzheimers Dis | observational | contradicts | moderate | NACC cohort study found lipid-lowering regimen (LLR, largely statins) use was associated with reduced yearly increase in CDR-SOB (i.e., slower cognitive/dementia progression) and improved survival, with no adverse effect on neurop |
| Reddin C, Stankard A, Chan KY, Krewer F, Judge C, Canavan M, Davis DHJ, O'Donnell M 2025 · Age Ageing | meta-analysis | contradicts | high | Meta-analysis finds lipid-lowering therapy including statins is not associated with increased cognitive impairment or dementia, if anything trending protective. |
Disagree, or know a study we missed?
We grade by evidence, not opinions. The way to weigh in is to point us to a study we haven't cited (check the evidence table above first), or to flag a problem with one we have. Every submission is reviewed; if it holds up, the grade updates and shows in Science Changes Its Mind.
Opens a short form. You'll sign in with Google so submissions are tied to a real account — we don't display your identity, and we only accept a link we can verify (PubMed, DOI, ClinicalTrials.gov).
Educational only, not medical advice. Grades and scores reflect published evidence weighted by study design and quality; see the methodology.